"Protalex, Inc., a clinical-stage biopharmaceutical company, today announced that following completion of a planned interim analysis of safety and efficacy data from the second dose cohort, the Company is escalating the dose of PRTX-100 in its U.S. Phase 1/2 study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-202 Study). One of the three patients treated in the second dose cohort achieved a protocol defined platelet response. Treatment of the first patient in the third cohort at a dose of 6.0 micrograms/kg, double that of the second dose cohort of 3.0 micrograms/kg, is expected soon."
- From Protalex Press Release
